Novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Conventional therapy and Pediatric Huatanzhike granules
Control group:Conventional therapy
Sponsors
First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age 18 to 80 years old (including threshold), sex unlimited, inpatient (2) Respiratory specimen were positive for COVID-19 nucleic acid by RT-PCR; (3) Clinical classification is mild or moderate type (with symptoms of fever, respiratory tract, imaging findings of pneumonia); (4) Hospitalization for the following reasons:Fever (axillary temperature >= 36.7 degrees C, or mouth temperature >= 38.0 degrees C, or anal or ear temperature >= 38.6 degrees C) and respiratory frequency > 24 beats/min or cough (Shortness of breath and cough at least one); (5) Informed consent signed.
Exclusion criteria
Exclusion criteria: (1) Patients with known or suspected to be allergic to the components of the test drug; (2) Patients with known hepatitis B, C, AIDS and other viral infections; (3) Patients with severe or severe clinical classification who have experienced complications such as respiratory failure and acute respiratory distress syndrome (ARDS); (4) Patients who have participated or are participating in other drug clinical trials within 2 weeks before screening; (5) Pregnancy: Positive pregnancy test for Female patients; (6) Patients may be transferred to non-participating hospitals within 72 hours; (7) Patients with respiratory infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and lung development; (8) Patients being treated with other Chinese medicine; (9) Believed to be not suitable to participate in clinical trials by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease; | — |
Countries
China
Contacts
Public ContactLiangdan Sun
First Affiliated Hospital of Anhui Medical University
Outcome results
None listed